Education
About Us
Working with TipRanks
Follow Us
Incyte (INCY)
:INCY
INCY Stock Chart & Stats
$103.89
$0.53(0.72%)
At close: 4:00 PM EST
$103.89
$0.53(0.72%)
Day’s Range― - ―
52-Week Range$53.56 - $109.28
Previous CloseN/A
Volume384.35K
Average Volume (3M)2.49M
Market Cap
$19.89B
Enterprise Value$14.19B
Total Cash (Recent Filing)$2.93B
Total Debt (Recent Filing)$41.27M
Price to Earnings (P/E)17.0
Beta0.42
Next Earnings
Feb 18, 2026EPS Estimate
1.92Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.26
Shares Outstanding196,322,710
10 Day Avg. Volume2,201,078
30 Day Avg. Volume2,491,137
Financial Highlights & Ratios
PEG Ratio-4.67
Price to Book (P/B)4.15
Price to Sales (P/S)3.37
P/FCF Ratio57.43
Enterprise Value/Market Cap0.71
Enterprise Value/Revenue2.95
Enterprise Value/Gross Profit3.21
Enterprise Value/Ebitda8.44
Forecast
1Y Price Target
$95.60Price Target Upside-7.98% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering19
EPS Forecast (FY)6.73
Revenue Forecast (FY)$4.97B
Bulls Say, Bears Say
Bulls Say
Investor ExpectationsIncyte shares have increased significantly over the past six months, indicating high investor expectations for INCA033989.
Pipeline OpportunitiesKey pipeline programs have blockbuster market opportunities and not all need to be successful for strong revenue growth potential longer term.
Revenue GuidanceThe company raised FY25 revenue guidance following strong performance in the third quarter.
Bears Say
Growth ConcernsJakafi growth continues to slow despite indication expansion in PV and GVHD.
Product DelaysIncyte delayed the initial readout of INCB160058 to the first half of 2026 from prior guidance of end of 2025 based on exposure levels of the drug coming below expectations.
Program DiscontinuationIncyte is discontinuing certain development programs due to regulatory feedback and competitive pressures.
Incyte News
INCY FAQ
What was Incyte’s price range in the past 12 months?
Incyte lowest stock price was $53.56 and its highest was $109.28 in the past 12 months.
What is Incyte’s market cap?
Incyte’s market cap is $19.89B.
When is Incyte’s upcoming earnings report date?
Incyte’s upcoming earnings report date is Feb 18, 2026 which is in 89 days.
How were Incyte’s earnings last quarter?
Incyte released its earnings results on Oct 28, 2025. The company reported $2.26 earnings per share for the quarter, beating the consensus estimate of $1.606 by $0.654.
Is Incyte overvalued?
According to Wall Street analysts Incyte’s price is currently Overvalued.
Does Incyte pay dividends?
Incyte does not currently pay dividends.
What is Incyte’s EPS estimate?
Incyte’s EPS estimate is 1.92.
How many shares outstanding does Incyte have?
Incyte has 196,322,710 shares outstanding.
What happened to Incyte’s price movement after its last earnings report?
Incyte reported an EPS of $2.26 in its last earnings report, beating expectations of $1.606. Following the earnings report the stock price went down -1.536%.
Which hedge fund is a major shareholder of Incyte?
Currently, no hedge funds are holding shares in INCY
Incyte Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$95.60 (-7.98% Downside)
$95.60 (-7.98% Downside)
Blogger Sentiment
Bullish
INCY Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 953.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $21.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.7%
Last 30 Days ▲ 94.8%
Last 30 Days ▲ 94.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
43.59%
12-Months-Change
Fundamentals
Return on Equity
30.39%
Trailing 12-Months
Asset Growth
26.29%
Trailing 12-Months
Company Description
Incyte
Incyte Corporation (INCY) is a biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines to treat serious diseases, primarily cancer and other hematologic disorders. The company operates in the oncology sector with a strong emphasis on targeted therapies and has a portfolio that includes both approved drugs and a pipeline of investigational products. Key products include Jakafi (ruxolitinib), a treatment for certain types of blood cancers, and other therapeutic candidates aimed at various malignancies and immunological conditions.
INCY Company Deck
INCY Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial performance and growth in key products like Jakafi and Opzelura. The launch of Niktimvo exceeded expectations. However, the decision to terminate certain programs due to regulatory and strategic priorities presented challenges. Overall, the sentiment was more positive given the revenue growth and successful product launches.View all INCY earnings summariesINCY Revenue Breakdown
85.33% Product revenues, net
13.66% Product royalty revenues
1.01% Milestone and contract revenues
INCY Stock 12 Month Forecast
Average Price Target
$95.60
▼(-7.98% Downside)
Technical Analysis
Ownership Overview
Currently, No data available
---